Sharlene Gill: Cholangiocarcinoma for sounding the alarm on access

Sharlene Gill shared on LinkedIn:

“Thank you Arndt Vogel, Rebecca Auer, and C3 Cholangiocarcinoma for sounding the alarm on access:

– FGFR2 fusions in cholangiocarcinoma are rare.
– FGFR inhibitors such as pemigatinib offer meaningful benefit, especially for patients who have no other options.
– Pemigatinib was approved by Health Canada in September 2021 but remains unfunded by CADTH.
– It was funded by Institut national d’excellence en santé et en services sociaux (INESSS) Quebec in November 2023, but the rest of Canada is out of luck.
– It is funded in several other countries but not in Canada.

How did this happen? It’s time to step up, Canada!”

Source: Sharlene Gill/LinkedIn

Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver, Canada.  Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee. 

She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.